Tag: GABA-A receptor positive allosteric modulator (intravenous anesthetic)

  • Propofol

    GABA-A receptor positive allosteric modulator (intravenous anesthetic)

    An alkylphenol intravenous general anesthetic; the most widely used induction anesthetic and the agent in Michael Jackson’s death.

    Abstract

    Propofol (2,6-diisopropylphenol; CAS 2078-54-8; molecular formula C12H18O; molecular weight 178.27) is an alkylphenol intravenous general anesthetic developed at ICI (now AstraZeneca) and approved by the FDA in 1989 (Diprivan). The compound is a GABA-A receptor positive allosteric modulator at a unique propofol-binding site distinct from the benzodiazepine, barbiturate, and steroid sites; the result is enhanced GABA-mediated chloride conductance and pronounced CNS depression. Formulation is a 1 percent oil-in-water emulsion (the source of the milky appearance). Plasma half-life is biphasic: rapid distribution (2 to 4 minutes) and slower elimination (3 to 12 hours). Approved indications: induction and maintenance of general anesthesia, sedation in ICU. Misuse for amateur sedation is associated with the death of Michael Jackson (2009). Propofol infusion syndrome (rare) involves metabolic acidosis, rhabdomyolysis, and cardiac failure with prolonged high-dose use. Used as the canonical IV anesthetic in research and clinical practice.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Etomidate

    GABA-A receptor positive allosteric modulator (intravenous anesthetic)

    An imidazole intravenous induction anesthetic; cardiovascular stable but causes adrenocortical suppression.

    Abstract

    Etomidate ((R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylic acid ethyl ester; CAS 33125-97-2; molecular formula C14H16N2O2; molecular weight 244.29) is an imidazole intravenous induction anesthetic developed at Janssen and approved by the FDA in 1972 (Amidate). The compound is a GABA-A receptor positive allosteric modulator with a binding site at the beta-2 and beta-3 subunits that produces preferential activity at extrasynaptic and synaptic GABA-A receptors. Distinct among IV anesthetics by minimal cardiovascular effects (preserved blood pressure and heart rate), making it preferred for patients with hemodynamic instability. The principal limitation is dose-dependent inhibition of 11-beta-hydroxylase (CYP11B1), the final enzyme in cortisol biosynthesis; even a single induction dose suppresses cortisol for 4 to 6 hours, with potential clinical consequence in critically ill patients. Plasma half-life is approximately 2 to 5 hours. Used as a reference IV anesthetic with cardiovascular stability and adrenocortical suppression.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.